FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3019395415> ?p ?o ?g. }

• W3019395415 endingPage "1466" @default.
• W3019395415 startingPage "1456" @default.
• W3019395415 abstract "Objective The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis ( RA ). Patients with RA have elevated interleukin‐6 ( IL ‐6) levels; however, the utility of IL ‐6 as a predictor of treatment response is unclear. This study was undertaken to investigate, by post hoc analysis, whether baseline IL ‐6 levels are predictive of sarilumab treatment responses in 2 phase III studies. Methods Serum IL ‐6 concentrations were measured in patients with RA prior to receiving sarilumab 200 mg (n = 148) or adalimumab 40 mg (n = 152) every 2 weeks (in the MONARCH trial; ClinicalTrials.gov identifier: NCT 02332590) or sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks plus methotrexate ( MTX ) (n = 401, n = 396, and n = 397, respectively) (in the MOBILITY trial; ClinicalTrials.gov identifier: NCT 01061736). Efficacy and patient‐reported outcomes were compared between and within groups according to IL ‐6 tertile using linear and logistic regression. Results In MONARCH , patients with high baseline IL ‐6 levels (all ≥3 times the upper limit of normal; n = 100) had higher disease activity at baseline than those with low IL ‐6 levels (n = 100). The magnitude of clinical improvement over 24 weeks with sarilumab versus adalimumab was greater in patients with high compared to those with low baseline IL ‐6 levels. In MOBILITY , compared to patients with low IL ‐6 levels (n = 397), patients with high IL ‐6 levels (n = 398) had higher disease activity and joint damage at baseline, were more likely to have joint progression, and had less clinical improvement over 52 weeks’ treatment with placebo plus MTX compared to sarilumab 150 mg or 200 mg plus MTX . Baseline IL ‐6 and C‐reactive protein levels were both predictive of outcomes. Safety profiles were similar between defined IL ‐6 tertiles. Conclusion IL ‐6 may be a prognostic marker of disease progression and severity, and patients with high IL ‐6 levels may be likely to benefit from sarilumab compared to adalimumab or MTX . Prospective validation is warranted to confirm the results of these post hoc analyses." @default.
• W3019395415 created "2020-05-01" @default.
• W3019395415 creator A5003819213 @default.
• W3019395415 creator A5027833091 @default.
• W3019395415 creator A5033861263 @default.
• W3019395415 creator A5039452184 @default.
• W3019395415 creator A5042703700 @default.
• W3019395415 creator A5048332998 @default.
• W3019395415 creator A5059504055 @default.
• W3019395415 creator A5076851275 @default.
• W3019395415 creator A5077395512 @default.
• W3019395415 creator A5082931235 @default.
• W3019395415 creator A5083583562 @default.
• W3019395415 creator A5085672493 @default.
• W3019395415 date "2020-08-25" @default.
• W3019395415 modified "2023-10-17" @default.
• W3019395415 title "Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis" @default.
• W3019395415 cites W1517711090 @default.
• W3019395415 cites W1586828706 @default.
• W3019395415 cites W1588610010 @default.
• W3019395415 cites W1985004174 @default.
• W3019395415 cites W2028014480 @default.
• W3019395415 cites W2106437519 @default.
• W3019395415 cites W2110177517 @default.
• W3019395415 cites W2120393706 @default.
• W3019395415 cites W2120792700 @default.
• W3019395415 cites W2128260735 @default.
• W3019395415 cites W2139316813 @default.
• W3019395415 cites W2141259520 @default.
• W3019395415 cites W2142004396 @default.
• W3019395415 cites W2143660712 @default.
• W3019395415 cites W2153216198 @default.
• W3019395415 cites W2159106700 @default.
• W3019395415 cites W2159705610 @default.
• W3019395415 cites W2419626675 @default.
• W3019395415 cites W2513662764 @default.
• W3019395415 cites W2514249865 @default.
• W3019395415 cites W2527818415 @default.
• W3019395415 cites W2530447981 @default.
• W3019395415 cites W2557016092 @default.
• W3019395415 cites W2733606048 @default.
• W3019395415 cites W2741797984 @default.
• W3019395415 cites W2765516039 @default.
• W3019395415 cites W2805636409 @default.
• W3019395415 cites W2809672010 @default.
• W3019395415 cites W2951829513 @default.
• W3019395415 cites W3014103961 @default.
• W3019395415 doi "https://doi.org/10.1002/art.41299" @default.
• W3019395415 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7496495" @default.
• W3019395415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32343882" @default.
• W3019395415 hasPublicationYear "2020" @default.
• W3019395415 type Work @default.
• W3019395415 sameAs 3019395415 @default.
• W3019395415 citedByCount "27" @default.
• W3019395415 countsByYear W30193954152020 @default.
• W3019395415 countsByYear W30193954152021 @default.
• W3019395415 countsByYear W30193954152022 @default.
• W3019395415 countsByYear W30193954152023 @default.
• W3019395415 crossrefType "journal-article" @default.
• W3019395415 hasAuthorship W3019395415A5003819213 @default.
• W3019395415 hasAuthorship W3019395415A5027833091 @default.
• W3019395415 hasAuthorship W3019395415A5033861263 @default.
• W3019395415 hasAuthorship W3019395415A5039452184 @default.
• W3019395415 hasAuthorship W3019395415A5042703700 @default.
• W3019395415 hasAuthorship W3019395415A5048332998 @default.
• W3019395415 hasAuthorship W3019395415A5059504055 @default.
• W3019395415 hasAuthorship W3019395415A5076851275 @default.
• W3019395415 hasAuthorship W3019395415A5077395512 @default.
• W3019395415 hasAuthorship W3019395415A5082931235 @default.
• W3019395415 hasAuthorship W3019395415A5083583562 @default.
• W3019395415 hasAuthorship W3019395415A5085672493 @default.
• W3019395415 hasBestOaLocation W30193954151 @default.
• W3019395415 hasConcept C126322002 @default.
• W3019395415 hasConcept C142724271 @default.
• W3019395415 hasConcept C204787440 @default.
• W3019395415 hasConcept C27081682 @default.
• W3019395415 hasConcept C2777575956 @default.
• W3019395415 hasConcept C2780132546 @default.
• W3019395415 hasConcept C2781059491 @default.
• W3019395415 hasConcept C67761136 @default.
• W3019395415 hasConcept C71924100 @default.
• W3019395415 hasConcept C90924648 @default.
• W3019395415 hasConceptScore W3019395415C126322002 @default.
• W3019395415 hasConceptScore W3019395415C142724271 @default.
• W3019395415 hasConceptScore W3019395415C204787440 @default.
• W3019395415 hasConceptScore W3019395415C27081682 @default.
• W3019395415 hasConceptScore W3019395415C2777575956 @default.
• W3019395415 hasConceptScore W3019395415C2780132546 @default.
• W3019395415 hasConceptScore W3019395415C2781059491 @default.
• W3019395415 hasConceptScore W3019395415C67761136 @default.
• W3019395415 hasConceptScore W3019395415C71924100 @default.
• W3019395415 hasConceptScore W3019395415C90924648 @default.
• W3019395415 hasFunder F4320311600 @default.
• W3019395415 hasFunder F4320333587 @default.
• W3019395415 hasIssue "9" @default.
• W3019395415 hasLocation W30193954151 @default.
• W3019395415 hasLocation W30193954152 @default.
• W3019395415 hasOpenAccess W3019395415 @default.

• next